The EFFECT OF Anti-miRNA 144 AND Anti-miRNA 150 ON THE EXPRESSION OF α GLOBIN CHAINS IN PBMC
Downloads
The excess of unbound α globin chains are the basic pathophysiology of the cause of clinical symptoms in major β thalassemia. Recently there are many alternative therapies by increasing γ globin chains to reduced the effects of unbound α globin chains. Alternative therapies by decreasing α globin chains have not been much noticed. α globin expression involves complex regulatory involving transcription factors and miRNAs. It involves GATA-1, KLFD and MYB transcription factors . It also involves miRNA-144 and miRNA-150. The role of miRNA-144 and miRNA-150 to reduce the α globin chains expression in major β thalassemia patients is an alternative therapy. miRNA-144 and miRNA150 activity need to be known by using anti-miRNA 144 and anti- miRNA 150. Analyzed the effect of anti-miRNA 144 and anti-miRNA 150 on the expression of α globin chains. This study was an experimental study using PBMC of a major β thalassemia patients. PBMC divided into four groups that were not transfected, transfected by anti-miRNA 144, transfected by anti-miRNA 150 and transfected by anti-miRNA 144 and anti-miRNA 150. qPCR examinations to find out expression of miRNA-144 and miRNA-150. Western blot examination to find out the expression of α globin chains. There was significantly lower miRNA-144 expression in PBMC of major β thalassemia patients who had been transfected by anti-miRNA 144 than those not transfected. In line with the result of miRNA-144 expression which was 0.17 times lower than the control group. There was significantly lower miRNA-150 expression in PBMC of major β thalassemia patients who had been transfected by anti-miRNA 150 than those not transfected. In line with the result of miRNA-150 expression which was 0.30 times lower than the control group. There was significantly lower α globin chains expression in PBMC thalassemia patients who had been transfected by anti-miRNA 150 than those not transfected. There was significantly lower α globin chains expression in PBMC thalassemia patients who had been transfected by anti-miRNA 150 and anti-miRNA 144 than those not transfected. This is evidenced by the decreased in the area 10-25 KDa band. Based on this study, the administration of anti-miRNA 150 or anti-miRNA 144 and anti-miRNA 150 is capable of decreasing the expression α globin chains in PBMC of major β thalassemia patients.
Colah, R., Gorakshakar, A., & Nadkarni, A. (2010). Global burden, distribution and pevention of thalassemias and hemoglobin E disorders. Expert Rev. Hematol, 3(1), 103–117.
Dreuzy, E., Bhukhai, K., Leboulch, P., & Payen, E. (2016). Current and future alternative therapies for beta-thalassemia major. Biomedical Journal, 36, 24–38.
Freisleben, S., Hidayat, J., Freisleben, H., Poertadji, S., Kurniawan, B., Bo, N., Handayani, S., Wahidiyat, P., & Soegianto, R. (2011). Plasma lipid pattern and red cell membrane structure in β-thalassemia patients in Jakarta. Med J Indones, 20(3), 178–184.
Higgs, D. (2004). Gene regulation in hematopoiesis: new lessons from thalassemia. American Society of Hematology, 65, 801–814.
Nienhuis, A., & Nathan, D. (2012). Pathophysiology and clinical manifestations of the β-Thalassemias. Cold Spring Harbor Perspectives in Medicine, 2, 1–13.
Panja, A., & Basu, A. (2015). Pharmacogenomics of the drugs used for the treatment of thalassemia. Cytology an Histology, 06, 360–362.
Ranjbaran, R., Okhovat, M., Mobarhanfard, A., Aboualizadeh, F., Abbasi, M., Moezzi, L., Golafshan, H., Behzad-Behbahani, A., Bagheri, M., & Sharifzadeh, S. (2014). Relationship between AHSP gene expression, β/α globin mRNA ratio, and clinical severity of β-thalasemia patients. Annals of Clinical and Laboratory Science, 44(2), 189–193.
Run, D., & Rachmilewitz, E. (2005). β-Thalassemia. The New England Journal of Medicine, 5(1), 12–15.
Tamam, M., Hadisaputro, S., Sutaryo, Setianingsih, I., Astuti, R., & Soemantri, A. (2010). Correlation between mutation type of globin gene and clinical manifestations of thalassemia. Jurnal Kedokteran Brawijaya, 26, 48–52.
Thein, S. (2005). Pathophysiologi of β-Thalassemia a guide to molecular therapies. American Society of Hematology Education Program, 5, 31–37.
Weatherall, D. (2011). The challenge of haemoglobinopathies in resource-poor countries. British Journal of Haematology, 154, 736–744.
Williams, T., & Weatherall, D. (2012). World distribution, population genetics, and health burden of the hemoglobinopathies. Cold Spring Harbor Perspectives in Medicine, 2, 67–68.
Copyright (c) 2023 Journal of Stem Cell Research and Tissue Engineering
This work is licensed under a Creative Commons Attribution 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without ristrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution (CC BY).
